Our comparative analysisof the inhibitory effects of the azolato-bridgedcomplexes on the proliferation of AR-positive prostate cancer cellline LNCaP, relative to the established Pt-drug cisplatin, revealednine compounds that demonstrated superior inhibitory effects (Figure 2A). Here, AR is linked to prostate carcinoma.